Kenai Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$8M
- Investors
-
6
Kenai Therapeutics General Information
Description
Developer of an induced pluripotent stem cell-based cell therapy platform designed to develop disease-modifying treatments for Parkinson's disease and other central nervous system conditions, operating in the biotechnology and cell therapy sector. The company offers cryopreserved, allogeneic, off-the-shelf neuron replacement therapies and a gene-modified cell therapy platform for central nervous system disorders, enabling patients and healthcare systems to access scalable regenerative treatment approaches targeting neurodegenerative disease mechanisms.
Contact Information
Website
www.kenaitx.comCorporate Office
- One Broadway
- 14th Floor Kendall Square
- Cambridge, MA 02142
- United States
Corporate Office
- One Broadway
- 14th Floor Kendall Square
- Cambridge, MA 02142
- United States
Kenai Therapeutics Timeline
Kenai Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 05-Jan-2026 | $8M | Completed | Clinical Trials - Phase 1 | ||
| 3. Early Stage VC (Series A) | 29-Feb-2024 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 26-Jan-2023 | $4M | $5M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 20-Jul-2022 | $5M | $5M | Completed | Pre-Clinical Trials |
Kenai Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Seed | 5,000,000 | $0.000010 | $1 | $1 | 1x | $1 | 1.88% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Kenai Therapeutics Comparisons
Industry
Financing
Details
Kenai Therapeutics Competitors (3)
One of Kenai Therapeutics’s 3 competitors is BlueRock Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BlueRock Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Aspen Neuroscience | Formerly VC-backed | San Diego, CA | ||||
| Sumitomo | Corporation | Tokyo, Japan |
Kenai Therapeutics Patents
Kenai Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026173911-A1 | Engineered cell therapy with secreted antibodies targeting lrrk2 | Pending | 11-Feb-2025 | ||
| WO-2026064194-A1 | Methods and compositions for dosing a cell therapy for parkinson's disease | Pending | 18-Sep-2024 | ||
| AU-2024334482-A1 | Methods and compositions for engineered da neuronal cells | Active | 31-Aug-2023 | ||
| AU-2024334482-C1 | Methods and compositions for engineered da neuronal cells | Active | 31-Aug-2023 | ||
| EP-4770680-A1 | Methods and compositions for engineered da neuronal cells | Pending | 31-Aug-2023 | C12N15/907 |
Kenai Therapeutics Signals
Kenai Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alaska Permanent Fund | Sovereign Wealth Fund | Minority | ||
| Cure Ventures | Venture Capital | Minority | ||
| Euclidean Capital | Family Office | Minority | ||
| The Column Group | Venture Capital | Minority | ||
| California Institute for Regenerative Medicine | Government |
Kenai Therapeutics FAQs
-
When was Kenai Therapeutics founded?
Kenai Therapeutics was founded in 2022.
-
Where is Kenai Therapeutics headquartered?
Kenai Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Kenai Therapeutics?
Kenai Therapeutics has 30 total employees.
-
What industry is Kenai Therapeutics in?
Kenai Therapeutics’s primary industry is Drug Discovery.
-
Is Kenai Therapeutics a private or public company?
Kenai Therapeutics is a Private company.
-
What is Kenai Therapeutics’s current revenue?
The current revenue for Kenai Therapeutics is .
-
How much funding has Kenai Therapeutics raised over time?
Kenai Therapeutics has raised $86.8M.
-
Who are Kenai Therapeutics’s investors?
Alaska Permanent Fund, Cure Ventures, Euclidean Capital, The Column Group, and California Institute for Regenerative Medicine are 5 of 6 investors who have invested in Kenai Therapeutics.
-
Who are Kenai Therapeutics’s competitors?
BlueRock Therapeutics, Aspen Neuroscience, and Sumitomo are competitors of Kenai Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process